Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment Ppublish
PubMed: 39037274 DOI: 10.1128/aac.00847-24
Case Commentary: Extending our therapeutic range against multidrug-resistant Candida.
Antimicrob Agents Chemother 68(8):e0084724
Authors: Max W Adelman, David R Andes
Affiliations
- Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
- Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
- Division of Pulmonary, Critical Care, and Sleep, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
- Weill Cornell Medicine, New York, New York, USA.
- Division of Infectious Diseases, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Abstract
Deep-seated Candida spp. infections may necessitate extended durations of antifungal therapy. Increasing resistance to first-line antifungals threatens the most common options for long-term treatment. In this issue, Ponta et al. (Antimicrob Agents Chemother 68:e00750-24, 2024, https://doi.org/10.1128/aac.00750-24) present cases in which they used rezafungin, a novel long-acting echinocandin antifungal, for extended durations. While excellent clinical evidence supports the short-term safety of rezafungin, these cases demonstrate that rezafungin may additionally have a role in long-term suppressive therapy for antifungal-resistant Candida spp. infections.
MeSH
Osteomyelitis, Drug Therapy, Endocarditis, Therapeutics, Anti-Bacterial Agents, Antifungal Agents, Antiviral Agents, Infections